US20160279401A1 - Dissolvable microneedles for skin treatment - Google Patents

Dissolvable microneedles for skin treatment Download PDF

Info

Publication number
US20160279401A1
US20160279401A1 US14/671,690 US201514671690A US2016279401A1 US 20160279401 A1 US20160279401 A1 US 20160279401A1 US 201514671690 A US201514671690 A US 201514671690A US 2016279401 A1 US2016279401 A1 US 2016279401A1
Authority
US
United States
Prior art keywords
microneedles
length
skin
array
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/671,690
Inventor
Justin J. Schwab
Michael Augarten
Zachary Dominguez
Ethan Franklin
Edwin J. Kayda
Jason Metzner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US14/671,690 priority Critical patent/US20160279401A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AUGARTEN, MIKE, METZNER, JASON, DOMINGUEZ, ZACHARY, FRANKLIN, ETHAN, KAYDA, EDWIN J., SCHWAB, JUSTIN
Publication of US20160279401A1 publication Critical patent/US20160279401A1/en
Priority to US15/903,262 priority patent/US10603477B2/en
Priority to US16/834,731 priority patent/US10987503B2/en
Priority to US17/240,884 priority patent/US20220080170A1/en
Priority to US18/130,490 priority patent/US20240033492A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/042Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • A61L2300/414Growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/428Vitamins, e.g. tocopherol, riboflavin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023Drug applicators using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046Solid microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0061Methods for using microneedles

Definitions

  • the present invention generally relates to skin treatment and rejuvenation, and more specifically relates to a skin treatment device including polymeric microneedles, and methods of treating skin using these devices.
  • Human dermis is a layer of skin between the epidermis and subcutaneous tissue.
  • the epidermis serves as a barrier to protect the body against microbial pathogens, oxidant stress (UV light), water loss and chemical compounds, and provides mechanical resistance.
  • the subcutaneous tissue consists of connective tissue and functions as a cushion for the body from stress and strain.
  • the dermis is tightly connected to the epidermis through a basement membrane. Structural components of the dermis are collagen, elastic fibers, glycosaminoglycan, and extra fibrillar matrix. The glycosaminoglycan, e.g.
  • hyaluronan has multiple functions such as, to ensure good hydration, to assist in the organization of the extracellular matrix (ECM), to act as a filler material, and to participate in tissue repair mechanisms.
  • ECM extracellular matrix
  • the extracellular matrix plays an important role in skin aging: in young skin, the collagen fibers form a three-dimensional network. The fibroblasts bind to collagen fibrils via multiple contact sites (integrins) on their surface. This binding builds up a tensile stress, which balances the synthesis of collagen and collagen-degrading matrix-metalloproteins in the fibroblasts. In aged skin, the structure of the extracellular matrix is damaged by collagen breakdown—partial fragmentation of the collagen.
  • Skin aging is a progressive phenomenon, occurs over time and can be affected by lifestyle factors, such as alcohol consumption, tobacco and sun exposure. Aging of the facial skin can be characterized by atrophy, slackening, and fattening. Atrophy corresponds to a massive reduction of the thickness of skin tissue. Slackening of the subcutaneous tissues leads to an excess of skin and ptosis and leads to the appearance of drooping cheeks and eye lids. Fattening refers to an increase in excess weight by swelling of the bottom of the face and neck. These changes are typically associated with dryness, loss of elasticity, and rough texture.
  • Non-invasive or low-invasive techniques and devices for facilitating delivery of beneficial agents into skin have been proposed.
  • microneedle devices have been used to create numerous shallow punctures in the dermis, with the goal of enabling better penetration of topical compositions into the punctured skin.
  • Such microneedle devices are used to perforate the skin and topical compositions are then sometimes applied to the punctured skin.
  • the present invention provides methods, devices and treatments for benefitting skin, for example, by enhancing penetration of skin for more effective delivery of drugs, pharmaceuticals, antioxidants, vitamins, and other beneficial agents.
  • a skin treatment device may include microneedles which are designed to more effectively deliver beneficial agents to the skin.
  • the device may comprise a substrate, and an arrangement, for example, an array of microneedles projecting from the substrate.
  • the microneedles may be comprised of a biodegradable polymer, for example, a polysaccharide, for example, hyaluronic acid.
  • the microneedles may further include an additive, for example, a vitamin or other beneficial agent.
  • the device is preferably designed such that the arrangement of microneedles will facilitate penetration of the microneedles into the skin, for example into the stratum corneum, when the device is applied to the skin.
  • the arrangement of microneedles comprises microneedles having different lengths from one another.
  • the array may comprise alternating first and second microneedles, wherein the first microneedles have a first length and second microneedles have a second length different from the first length.
  • the device may include a first region sized and/or shaped to cover a first portion of skin to be treated, and a second region adjacent and connected to the first region, the second region sized and/or shaped to cover a second portion of skin to be treated.
  • the first region includes first microneedles projecting from the substrate and having a first length
  • the second region includes second microneedles projecting from the substrate and having a second length, different from the first length, projecting from the first region and second microneedles having a second height different from the first height, projecting from the second region.
  • a method of treating skin comprises the step of facilitating penetration of microneedles into skin by drawing an area of skin to be treated toward an array of microneedles, for example using suction or a vacuum.
  • a skin treatment assembly comprising a first patch having a first shape for covering a portion of a face to be treated and including a first array of microneedles and a second patch having a second shape different from the first shape for covering another portion of a face to be treated and including a second array of microneedles different from the first array.
  • the first array comprises microneedles having a first length and the second array comprises microneedles having a second length different from the first length. In other embodiments, the first array comprises microneedles having a first spacing and the second array comprises microneedles having a second spacing different from the first spacing.
  • FIG. 1 shows an SEM image of a portion of a PRIOR ART microneedle device
  • FIGS. 2 a -2 c illustrate, in simplified form, the mechanism of action of the PRIOR ART microneedle device shown in FIG. 1 ;
  • FIGS. 3 a -3 c illustrate, in simplified form, a mechanism of action of a microneedle device of an embodiment of the present invention
  • FIG. 4 shows a balloon representing skin, being pressed against an array of nails representing a PRIOR ART microneedle array
  • FIGS. 5 a and 5 b show, in simplified form, an array of microneedles in some embodiments of the invention, and penetration of skin thereby;
  • FIGS. 6 a and 6 b show, in simplified form, an array of microneedles in other embodiments of the invention, and penetration of skin thereby;
  • FIG. 7 shows yet another embodiment of the invention
  • FIG. 8 illustrates an assembly in accordance with some embodiments of the invention, useful for treating skin using layered microneedle devices
  • FIGS. 9 and 10 illustrate, in simplified form, embodiments of the invention using negative pressure to enhance effectiveness of the present invention.
  • FIGS. 11, 12 and 13 illustrate yet other embodiments of the invention.
  • FIG. 1 a SEM image of a portion of a PRIOR ART microneedle device 1 is shown.
  • the microneedles 2 have a uniform length, shape and spacing. As illustrated in FIG. 2 a through 2 c , the microneedles 2 are generally used to prick or penetrate skin 3 at very superficial, shallow depths ( FIG. 2 a ), to mechanically make the skin 3 more porous ( FIG. 2 b ) and, theoretically, to permit penetration of topical agents 4 into the deeper layers of the skin ( FIG. 2 c ).
  • polymeric microneedles, and arrays of such microneedles, coupled with both simple and complex geometries and arrangements, have been developed for more effectively delivering pharmaceuticals, drugs, and other beneficial agents to skin. Delivery of such agents and ingredients may enhance the look and feel of the skin, by promoting hydration and improving skin texture and elasticity.
  • the microneedles comprise a biocompatible polymeric material.
  • the microneedles comprise a polymeric material that is biodegradable or dissolvable in skin.
  • the microneedles comprise a mixture of a polymeric material and an active agent beneficial to skin.
  • Suitable polymeric materials include polymethylmethacrylate (PMMA), poly(glycolic acid-co-lactic acid) (PLGA), polyethylene (PE), polycaprolactone (PCL), polypropylene.
  • the polymeric materials may comprise a glycosaminoglycans (GAG), such as hyaluronan, chondroitin, heparin, collagen, fibroin, elastin, various polysaccharides, cellulose derivatives, and the like.
  • the microneedles comprise a blend or combination of different polymers.
  • the beneficial agent may be any beneficial ingredient for improving skin, for example improving skin health, texture, hydration, or elasticity.
  • beneficial agents include vitamins (for example, A, C, B), antioxidants, skin-whitening agents, peptides and growth factors.
  • the polymeric material is a polysaccharide, for example, hyaluronic acid.
  • the beneficial agent and the polymeric material are both hyaluronic acid.
  • the polymeric material is a crosslinked polymer, for example, crosslinked hyaluronic acid. Crosslinking of hyaluronic acid may be accomplished in any suitable manner known to those of skill in the art.
  • a precursor composition for example, a polymeric gel composition including, or without, one or more beneficial additives.
  • the precursor composition may be made using known techniques for example, known techniques for making hyaluronic acid-based dermal filler gels.
  • the gel may be formed into gel microneedles using, for example, micromolding technologies.
  • the microneedles project from a substrate to facilitate handling.
  • the substrate may be the same material as the microneedles, or may be a different material.
  • the substrate may be any suitable flexible substrate, such as a fabric, sheet or membrane.
  • the formed gel microneedles may be then be allowed to become, or may be caused to become, dried, hardened projections that will penetrate skin.
  • Hyaluronic acid is a non-sulfated glycosaminoglycan that enhances water retention and resists hydrostatic stresses. It is non-immunogenic and can be chemically modified in numerous fashions. Hyaluronic acid may be anionic at pH ranges around or above the pKa of its carboxylic acid groups. Unless clearly indicated otherwise, reference to hyaluronic acid, hyaluronan, or HA herein may include its fully protonated, or nonionic form as depicted below, as well as any anionic forms and salts of hyaluronic acid, such as sodium salts, potassium salts, lithium salts, magnesium salts, calcium salts, etc.
  • a skin treatment device 10 which allows for a “poke, dissolve and release” mechanism.
  • the device 10 may comprise a substrate 11 , and an arrangement, for example, an array, of microneedles 12 projecting from the substrate 11 ( FIG. 3 a ).
  • the microneedles 12 comprise a polymeric component and an active pharmaceutical, drug or other beneficial agent.
  • the agent may be combined with, mixed in, encapsulated, or crosslinked with or into, the polymer component.
  • the microneedles 12 are structured to be capable of penetrating the skin 3 ( FIG. 3 b ), for example, the epidermis, and are released in the tissues below the skin surface and dissolved ( FIG. 3 c ). Dissolution of the polymeric component of the microneedle causes release of the beneficial agent into the skin, for example, as the polymer breaks down, biodegrades or dissolves.
  • FIG. 4 An inflated balloon 5 is used to represent skin, and an array 6 of nails 7 with identical lengths is used to represent a prior art microneedle device having microneedles all of the same length. As illustrated, the nail tips are generally unable to penetrate or puncture through the balloon 5 , or at least not without substantial pressures being applied between the balloon and the array of nails.
  • a skin treatment device 20 comprising a microneedle array 22 comprising microneedles projecting from a substrate 26 .
  • the microneedle array 22 comprises needles of differing or varying lengths (sometimes referred to as “heights.”
  • the device 20 comprises first microneedles 32 having a first length and second microneedles 34 having a second length different from the first length.
  • First microneedles 32 and second microneedles 34 may be disposed in an alternating fashion, for example, in ones, twos, threes, or more.
  • the microneedles 32 , 34 may be arranged in a set pattern or may be arranged randomly.
  • the first length is at least about 1% greater in length than the second length.
  • the first length is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 300%, at least about 500%, at least about 800%, or at least about 1000% greater in length than the second length.
  • the first microneedles may have a length that is at least about 10% to about 200% greater than the length of the second microneedles.
  • the first microneedles have a length that is about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 100%, or about 110%, or about 120%, or about 130%, or about 140%, or about 150%, or about 160%, or about 170%, or about 180%, or about 190%, or about 200% or greater than the length of the second microneedles.
  • the device 20 is structured to be more effective in penetrating skin 4 , for example, relative to an otherwise identical PRIOR ART device 1 having needles all of the same length, such as described above.
  • the pressure of individual tall needles, for example, needles 32 is increased and therefore potentially increases the number and amount of microneedles ultimately capable of penetrating the skin. This might be better appreciated by referring to FIG. 5 b.
  • the microneedles 32 , 34 may comprise a mixture of a polymeric material and an active agent beneficial to skin.
  • the array 22 may be formed by molding the microneedles 32 , 34 using conventional molding techniques.
  • FIGS. 6 a and 6 b Another embodiment of the invention is shown in FIGS. 6 a and 6 b .
  • a device 40 similar to device 20 , is provided, which comprises array 41 comprising microneedles 42 , 44 , 46 of at least three or more different lengths.
  • microneedles are provided which have a beneficial depth of penetration, depending upon the patient's age, skin type, and/or area of skin being treated.
  • a skin treatment device which comprises a substrate having a first region including microneedles having a first length, and a second region adjacent the first region and including microneedles having a second length that is different from the first length.
  • a patch device 50 that includes certain regions with particular needle arrays, which takes into account variances in dermal thicknesses of a patient. This may facilitate efficient drug delivery to various areas of the face, for example.
  • device 50 is in the form of a patch having array 52 for the nose bridge, and a different array 54 for the thinner facial region adjacent the nose.
  • the device 50 is thus in the form of a single patch that is capable of effectively delivering drugs or beneficial agents to different regions of the skin, in this case, the nose bridge and the cheeks and/or tear trough, at a depth of penetration suitable for the skin region, based on the different arrangements of microneedles.
  • the depth of penetration may be between about 25 ⁇ m to about 2000 ⁇ m, for example, about 100 ⁇ m to about 1000 ⁇ m.
  • the microneedles have a length of less than 100 ⁇ m, and in some embodiments, the microneedles have a length of greater than 1000 ⁇ m, for example, up to about 2000 ⁇ m.
  • the microneedles for example, the longest microneedles in the arrangement, have a length of between about 200 ⁇ m and about 600 ⁇ m, for example, about 400 ⁇ m, or even more specifically, about 420 ⁇ m to about 480 ⁇ m.
  • a skin treatment device in accordance with the invention comprises a substrate and spaced apart hyaluronic acid-based microneedles projecting from the substrate, wherein the microneedles have a length of between about 420 ⁇ m and 480 ⁇ m, a base of between about 200 ⁇ m and about 300 ⁇ m, for example, a base of about 270 ⁇ m, and a tip width of less than 20 ⁇ m, for example, a tip width of about 5 ⁇ m.
  • the microneedles for example, the first microneedles, have a length less than about 500 ⁇ m, for example, between about 100 ⁇ m to about 500 ⁇ m, for example, a length of about 400 ⁇ m, for example, a length of about 300 ⁇ m, for example, a length of about 200 ⁇ m.
  • the microneedles have a length greater than about 500 ⁇ m, for example, a length of between about 500 ⁇ m to about 2000 ⁇ m, for example, a length of about 600 ⁇ m, for example, a length of about 700 ⁇ m, for example, a length of about 800 ⁇ m, for example, a length of up to about 1000 ⁇ m, of up to about 2000 ⁇ m.
  • the first microneedles have a length of about 1000 ⁇ m and the second microneedles have a length of about 500 ⁇ m.
  • the first microneedles may be in the region of the patch for application on the nose of the patient, where the skin in relatively thick, and the second microneedles may be in a region of the patch that is intended for the regions of skin directly adjacent the nose, where the skin is relatively thin.
  • the first microneedles have a length of about 800 ⁇ m and the second microneedles have a length of about 200 ⁇ m. In yet another embodiment, the first microneedles have a length of about 500 ⁇ m and the second microneedles have a length of about 300 ⁇ m.
  • the device may comprise microneedles having a third length different from the first and second length, and a fourth length different from the first second and third lengths.
  • Spacing between adjacent microneedles may be uniform or non-uniform across the microneedle arrangement.
  • spacing between microneedles is substantially uniform. Spacing may be between about 100 ⁇ m and about 2000 ⁇ m, for example, 200 ⁇ m, about 300 ⁇ m, about 400 ⁇ m, about 500 ⁇ m, about 600 ⁇ m, about 700 ⁇ m, about 800 ⁇ m, about 900 ⁇ m, about 1000 ⁇ m, about 1100 ⁇ m, about 1200 ⁇ m, about 1300 ⁇ m, about 1400 ⁇ m, about 1500 ⁇ m, about 1600 ⁇ m, about 1700 ⁇ m, about 1800 ⁇ m, about 1900 ⁇ m, or about 2000 ⁇ m, or greater, between adjacent microneedles.
  • the present invention provides a skin treatment device 70 comprising a plurality of stages, or layers 72 , 74 , 76 , 78 .
  • the layers 72 , 74 , 76 , 78 may be designed to be applied to the skin in an overlapping fashion.
  • the device 70 provides custom treatment for a patient depending upon the type of skin, or the amount or type of active agent to be delivered. For example, device 70 may be used to create different layered microneedle patches 80 , 82 , each tailored to a patient's unique skin qualities.
  • Each of the layers may comprise a substrate 72 having spacing or perforations 72 and microneedles 72 a located generally between the spacing.
  • the needles 72 a may be throttled to permit a number of layers to be stacked on one another, with needles of adjacent layers extending in the spacing between needles of other adjacent layers.
  • layered patch 80 comprising fewer layers 72 , 74 , and thus a lower density of needles, may be utilized to treat the skin.
  • a patch 82 comprising more layers, such as layers 72 , 74 , 76 and 78 , and thus a higher density of needles, could be used to treat the skin.
  • a single layer for example, layer 72 may be used for treatment of a patient having rough, more deflective skin.
  • a layered patch 80 comprising a combination of layer 72 and layer 74 , may be used for treatment of a patient having semi-rough, less deflective skin.
  • a patient with relatively smooth skin may be treated with a denser needle array, for example, a layered patch 82 comprising a combination of layers 72 , 74 , 76 and 78 .
  • the layers 72 , 74 , 76 , 78 could be pre-assembled before being applied to the skin, or could be layered during a treatment session while on the skin.
  • each of layers 72 , 74 , 76 and 78 comprises a different specific needle length, such that when the layers are placed together, the assembly provides a desired treatment profile.
  • layer 72 may include only relatively long needles 72 a and layer 78 may comprise only relatively short needles 78 a .
  • each layer comprises needles of appropriate needle length to effectively deliver an equivalent amount of active agent per needle.
  • each of layers 72 , 74 , 76 and 78 comprises a different, specific pharmaceutical, or other beneficial agent, such that when the layers are placed together, the assembly provides a desired treatment profile, for example, made up of a combination of such agents.
  • layer 72 may include needles 72 a comprising hyaluronic acid and Vitamin C as an active agent, while layer 74 includes needles 74 a having hyaluronic acid and Vitamin E as an active agent.
  • patch 80 comprising layered 72 and 74 , can be used to deliver both hyaluronic acid, Vitamin C and Vitamin E.
  • a method of treating skin comprises drawing an area of skin 3 to be treated toward a microneedle device, for example, device 10 , or any other microneedle device in accordance with the invention as described elsewhere herein.
  • the method comprises using negative pressure, for example by means of a vacuum mechanism 90 having vacuum chamber 92 , in order to stretch the skin and enhance penetration of microneedles into the skin 3 . This method reduces deflection of the skin away from the needles and improves the number of needles that penetrate the skin and/or depth of needle penetration.
  • the vacuum mechanism 90 includes essentially no moving parts, and vacuum chamber 92 supplies negative pressure to draw the surface of skin 3 toward microneedle device 10 .
  • the microneedle device 10 can be flexibly sealed against the walls of the chamber such as by means of a rubber or other suitable material gasket, thus allowing the device 10 to move toward skin while maintaining a vacuum.
  • the skin 3 may experience maximum deflection in the central area within the vacuum chamber 92 . It is contemplated that in order to compensate for uneven deflection, the microneedles at the perimeter of the device 10 can be made longer than the needles in the inner portion thereof. Another means to address uneven skin deflection caused by the vacuum is to provide an appropriately sized vacuum area so that the micro-needle penetration area is sufficient for therapeutic coverage but small enough to permit consistency. For example, as illustrated in FIG. 10 , multiple vacuum chambers 94 , for example, seven vacuum chambers, located within a single housing 96 , may be used to provide more consistent needle penetration and to enable coverage of a larger skin area in single application.
  • device 110 of the invention is in the form of a stretchable mask.
  • Device 110 may be similar to devices 10 , 20 , 40 , 50 , 70 , 80 and 82 , and may include one or more of the features already described.
  • Device 110 may have substrate in a generic face shape, for example, with cutouts 112 for the eyes, lips, and/or and any other areas. Either the substrate only, or the entire device 110 including the microneedles, can be made of a stretchable material.
  • arrangements of microneedles of the device 110 can be different for treating different locations of the face.
  • the needle length, density of needles, or needle geometry can be altered depending on the region of the face they are intended to treat.
  • microneedles 112 are provided for treatment below the eye
  • microneedles 112 b are provided for treatment of the cheek region
  • microneedles 112 c are provided for treatment of the chin region.
  • device 210 is provided which comprises separate, discrete patches 212 are provided for specific areas of the face. This is illustrated in FIG. 12 .
  • the ability of the discrete patches to overlap allows the patches to accommodate many potential face shapes and sizes.
  • area specific microneedle patches are applied independently across a patient's face.
  • Each patch may include the same or different arrangements of microneedles, for example, arrangements 212 a , 212 b , 212 c .
  • the needle length, density of needles, type or dosage of beneficial agent, or even needle geometry can be altered depending on where on the region of the face they will be used to treat.
  • FIG. 13 Another embodiment, illustrated in FIG. 13 , is provided which generally comprises an assembly 310 comprising microneedle strips 312 which may be applied to skin in rows, or other patterns, to obtain the precise coverage desirable for a patient.
  • Such strips 312 may be provided in the form of a roll 314 of tape 316 .
  • the tape 314 may have features that indicate which side of the tape contains the microneedles. This may be a color, text, or shape indication. This embodiment allows rapid large surface area application over a wide variety of patient anatomies.
  • strip “types” may be provided that can be used during a single procedure. Each strip may be used on specific areas of the face, with needles on each strip with unique needle length, density of needles, needle geometry, etc.
  • the microneedle geometries may be unique to specific “tapes” to be applied on certain regions of the face.
  • HA gel hydrates were made by hydrating low molecular weight (LMW) HA (Mw is about 340,000 to about 840,000 Da) in deionized (DI) water or phosphate buffered saline (PBS).
  • LMW low molecular weight
  • DI deionized
  • PBS phosphate buffered saline
  • the casting of HA gel includes two steps, casting and pre-concentrating.
  • HA gel was cast on the negative silicone microneedle mold and upon evaporation of water at room temperature or in an oven, the solution formed a viscous paste on the top of the mold.
  • 0.65 mL of a 12 wt % HA gel was cast onto the center of the negative silicone mold.
  • the gel together with the silicone mold was placed into an oven which was pre-set at 40° C. After 1.50 hours of incubation, the gel formed a paste and was removed from the oven for the compression step.
  • the HA paste together with the negative silicone microneedle mold was placed on a compressor.
  • a PTFE film was placed on top of the HA paste.
  • the compression pressure was set to 20 psi initially, then increased to 50 psi at a constant rate over a period of 30 seconds and held at this pressure for another 30 seconds.
  • the PTFE film was removed and a flat layer of HA remained on top of the mold.
  • the mold was then placed into a 40° C. oven for 2.5 hours.
  • the dried micro-needle batch was then removed from the mold and sent for characterizations by SEM and x-ray CT.

Abstract

A skin treatment device is provided including bioerodible polymeric microneedles which are designed to more effectively deliver beneficial agents to the skin. The device includes a flexible substrate and an arrangement, for example, an array, of microneedles projecting from the substrate.

Description

  • This application claims priority to and the benefit of U.S. Provisional Patent Application No. 61/972,165, filed on Mar. 28, 2014, the entire disclosure of which is incorporated herein by this specific reference.
  • The present invention generally relates to skin treatment and rejuvenation, and more specifically relates to a skin treatment device including polymeric microneedles, and methods of treating skin using these devices.
  • BACKGROUND
  • Human dermis is a layer of skin between the epidermis and subcutaneous tissue. The epidermis, serves as a barrier to protect the body against microbial pathogens, oxidant stress (UV light), water loss and chemical compounds, and provides mechanical resistance. The subcutaneous tissue consists of connective tissue and functions as a cushion for the body from stress and strain. The dermis is tightly connected to the epidermis through a basement membrane. Structural components of the dermis are collagen, elastic fibers, glycosaminoglycan, and extra fibrillar matrix. The glycosaminoglycan, e.g. hyaluronan, has multiple functions such as, to ensure good hydration, to assist in the organization of the extracellular matrix (ECM), to act as a filler material, and to participate in tissue repair mechanisms. The extracellular matrix plays an important role in skin aging: in young skin, the collagen fibers form a three-dimensional network. The fibroblasts bind to collagen fibrils via multiple contact sites (integrins) on their surface. This binding builds up a tensile stress, which balances the synthesis of collagen and collagen-degrading matrix-metalloproteins in the fibroblasts. In aged skin, the structure of the extracellular matrix is damaged by collagen breakdown—partial fragmentation of the collagen.
  • Skin aging is a progressive phenomenon, occurs over time and can be affected by lifestyle factors, such as alcohol consumption, tobacco and sun exposure. Aging of the facial skin can be characterized by atrophy, slackening, and fattening. Atrophy corresponds to a massive reduction of the thickness of skin tissue. Slackening of the subcutaneous tissues leads to an excess of skin and ptosis and leads to the appearance of drooping cheeks and eye lids. Fattening refers to an increase in excess weight by swelling of the bottom of the face and neck. These changes are typically associated with dryness, loss of elasticity, and rough texture.
  • To improve cell function of skin, there are two main approaches: one is to supply skin cells with essential building blocks through oral nutrition and supplements or topical creams and serums or vigorous daily exercise to increase blood-flow and encourage the lymphatic system; the other approach relates to optimizing release of growth factors, i.e. substances that cause cells to differentiate, proliferate and/or grow, and cytokines which signal molecules released by cells to communicate with other cells. However, applying active ingredients topically to skin in order to improve cell function has generally not been highly effective, likely due to the impermeable nature of stratum corneum and other superficial layers of the epidermis.
  • Non-invasive or low-invasive techniques and devices for facilitating delivery of beneficial agents into skin have been proposed. For example, microneedle devices have been used to create numerous shallow punctures in the dermis, with the goal of enabling better penetration of topical compositions into the punctured skin. Such microneedle devices are used to perforate the skin and topical compositions are then sometimes applied to the punctured skin.
  • There remains an unmet need for better methods, devices and treatments for improving skin conditions, for example, in order to optimize skin health and improve outward appearance.
  • SUMMARY
  • The present invention provides methods, devices and treatments for benefitting skin, for example, by enhancing penetration of skin for more effective delivery of drugs, pharmaceuticals, antioxidants, vitamins, and other beneficial agents.
  • In one embodiment, a skin treatment device is provided. The device may include microneedles which are designed to more effectively deliver beneficial agents to the skin. The device may comprise a substrate, and an arrangement, for example, an array of microneedles projecting from the substrate. The microneedles may be comprised of a biodegradable polymer, for example, a polysaccharide, for example, hyaluronic acid. The microneedles may further include an additive, for example, a vitamin or other beneficial agent.
  • The device is preferably designed such that the arrangement of microneedles will facilitate penetration of the microneedles into the skin, for example into the stratum corneum, when the device is applied to the skin. For example, in some embodiments, the arrangement of microneedles comprises microneedles having different lengths from one another. For example, the array may comprise alternating first and second microneedles, wherein the first microneedles have a first length and second microneedles have a second length different from the first length.
  • In some embodiments, the device may include a first region sized and/or shaped to cover a first portion of skin to be treated, and a second region adjacent and connected to the first region, the second region sized and/or shaped to cover a second portion of skin to be treated. In some embodiments, the first region includes first microneedles projecting from the substrate and having a first length, and the second region includes second microneedles projecting from the substrate and having a second length, different from the first length, projecting from the first region and second microneedles having a second height different from the first height, projecting from the second region.
  • Methods of treating skin are also provided. In one embodiment, a method of treating skin comprises the step of facilitating penetration of microneedles into skin by drawing an area of skin to be treated toward an array of microneedles, for example using suction or a vacuum.
  • In yet another aspect of the invention, a skin treatment assembly is provided comprising a first patch having a first shape for covering a portion of a face to be treated and including a first array of microneedles and a second patch having a second shape different from the first shape for covering another portion of a face to be treated and including a second array of microneedles different from the first array.
  • In some embodiments, the first array comprises microneedles having a first length and the second array comprises microneedles having a second length different from the first length. In other embodiments, the first array comprises microneedles having a first spacing and the second array comprises microneedles having a second spacing different from the first spacing.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The present invention may be more readily understood and/or the advantages thereof better appreciated by considering the following Detailed Description and accompanying drawings of which:
  • FIG. 1 shows an SEM image of a portion of a PRIOR ART microneedle device;
  • FIGS. 2a-2c illustrate, in simplified form, the mechanism of action of the PRIOR ART microneedle device shown in FIG. 1;
  • FIGS. 3a-3c illustrate, in simplified form, a mechanism of action of a microneedle device of an embodiment of the present invention;
  • FIG. 4 shows a balloon representing skin, being pressed against an array of nails representing a PRIOR ART microneedle array;
  • FIGS. 5a and 5b show, in simplified form, an array of microneedles in some embodiments of the invention, and penetration of skin thereby;
  • FIGS. 6a and 6b show, in simplified form, an array of microneedles in other embodiments of the invention, and penetration of skin thereby;
  • FIG. 7 shows yet another embodiment of the invention;
  • FIG. 8 illustrates an assembly in accordance with some embodiments of the invention, useful for treating skin using layered microneedle devices;
  • FIGS. 9 and 10 illustrate, in simplified form, embodiments of the invention using negative pressure to enhance effectiveness of the present invention; and
  • FIGS. 11, 12 and 13 illustrate yet other embodiments of the invention.
  • DETAILED DESCRIPTION
  • Turning to FIG. 1, a SEM image of a portion of a PRIOR ART microneedle device 1 is shown. The microneedles 2 have a uniform length, shape and spacing. As illustrated in FIG. 2a through 2c , the microneedles 2 are generally used to prick or penetrate skin 3 at very superficial, shallow depths (FIG. 2a ), to mechanically make the skin 3 more porous (FIG. 2b ) and, theoretically, to permit penetration of topical agents 4 into the deeper layers of the skin (FIG. 2c ).
  • In accordance with the present invention, polymeric microneedles, and arrays of such microneedles, coupled with both simple and complex geometries and arrangements, have been developed for more effectively delivering pharmaceuticals, drugs, and other beneficial agents to skin. Delivery of such agents and ingredients may enhance the look and feel of the skin, by promoting hydration and improving skin texture and elasticity.
  • In one aspect of the invention, the microneedles comprise a biocompatible polymeric material. In some embodiments, the microneedles comprise a polymeric material that is biodegradable or dissolvable in skin. In some embodiments, the microneedles comprise a mixture of a polymeric material and an active agent beneficial to skin.
  • Suitable polymeric materials include polymethylmethacrylate (PMMA), poly(glycolic acid-co-lactic acid) (PLGA), polyethylene (PE), polycaprolactone (PCL), polypropylene. The polymeric materials may comprise a glycosaminoglycans (GAG), such as hyaluronan, chondroitin, heparin, collagen, fibroin, elastin, various polysaccharides, cellulose derivatives, and the like. In some embodiments, the microneedles comprise a blend or combination of different polymers.
  • The beneficial agent may be any beneficial ingredient for improving skin, for example improving skin health, texture, hydration, or elasticity. Such agents include vitamins (for example, A, C, B), antioxidants, skin-whitening agents, peptides and growth factors.
  • In some embodiments, the polymeric material is a polysaccharide, for example, hyaluronic acid. In some embodiments, the beneficial agent and the polymeric material are both hyaluronic acid. In some embodiments, the polymeric material is a crosslinked polymer, for example, crosslinked hyaluronic acid. Crosslinking of hyaluronic acid may be accomplished in any suitable manner known to those of skill in the art.
  • To make the present microneedle devices, a precursor composition is provided, for example, a polymeric gel composition including, or without, one or more beneficial additives. The precursor composition may be made using known techniques for example, known techniques for making hyaluronic acid-based dermal filler gels. The gel may be formed into gel microneedles using, for example, micromolding technologies. The microneedles project from a substrate to facilitate handling. The substrate may be the same material as the microneedles, or may be a different material. The substrate may be any suitable flexible substrate, such as a fabric, sheet or membrane. The formed gel microneedles may be then be allowed to become, or may be caused to become, dried, hardened projections that will penetrate skin.
  • Hyaluronic acid is a non-sulfated glycosaminoglycan that enhances water retention and resists hydrostatic stresses. It is non-immunogenic and can be chemically modified in numerous fashions. Hyaluronic acid may be anionic at pH ranges around or above the pKa of its carboxylic acid groups. Unless clearly indicated otherwise, reference to hyaluronic acid, hyaluronan, or HA herein may include its fully protonated, or nonionic form as depicted below, as well as any anionic forms and salts of hyaluronic acid, such as sodium salts, potassium salts, lithium salts, magnesium salts, calcium salts, etc.
  • Figure US20160279401A1-20160929-C00001
  • Turning now to FIGS. 3a-3c , in one aspect, a skin treatment device 10 is provided which allows for a “poke, dissolve and release” mechanism. For example, the device 10 may comprise a substrate 11, and an arrangement, for example, an array, of microneedles 12 projecting from the substrate 11 (FIG. 3a ). The microneedles 12 comprise a polymeric component and an active pharmaceutical, drug or other beneficial agent. The agent may be combined with, mixed in, encapsulated, or crosslinked with or into, the polymer component. The microneedles 12 are structured to be capable of penetrating the skin 3 (FIG. 3b ), for example, the epidermis, and are released in the tissues below the skin surface and dissolved (FIG. 3c ). Dissolution of the polymeric component of the microneedle causes release of the beneficial agent into the skin, for example, as the polymer breaks down, biodegrades or dissolves.
  • One drawback with PRIOR ART microneedle technology, such as the microneedles shown with FIG. 1 described above is that all of the needles are of the same shape, length and are uniformly spaced apart. However, the natural elasticity of skin often prevents individual needles from effectively penetrating the skin. This concept is graphically illustrated in FIG. 4. An inflated balloon 5 is used to represent skin, and an array 6 of nails 7 with identical lengths is used to represent a prior art microneedle device having microneedles all of the same length. As illustrated, the nail tips are generally unable to penetrate or puncture through the balloon 5, or at least not without substantial pressures being applied between the balloon and the array of nails.
  • Advantageously, referring now to FIGS. 5a-5c , in some embodiments of the invention, a skin treatment device 20 is provided comprising a microneedle array 22 comprising microneedles projecting from a substrate 26. The microneedle array 22 comprises needles of differing or varying lengths (sometimes referred to as “heights.” For example, the device 20 comprises first microneedles 32 having a first length and second microneedles 34 having a second length different from the first length. First microneedles 32 and second microneedles 34 may be disposed in an alternating fashion, for example, in ones, twos, threes, or more. The microneedles 32, 34 may be arranged in a set pattern or may be arranged randomly.
  • In some embodiments, the first length is at least about 1% greater in length than the second length. For example, in some embodiments, the first length is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 300%, at least about 500%, at least about 800%, or at least about 1000% greater in length than the second length. In some embodiments, the first microneedles may have a length that is at least about 10% to about 200% greater than the length of the second microneedles. For example, the first microneedles have a length that is about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 100%, or about 110%, or about 120%, or about 130%, or about 140%, or about 150%, or about 160%, or about 170%, or about 180%, or about 190%, or about 200% or greater than the length of the second microneedles.
  • The device 20 is structured to be more effective in penetrating skin 4, for example, relative to an otherwise identical PRIOR ART device 1 having needles all of the same length, such as described above. By alternating needle length, the pressure of individual tall needles, for example, needles 32, is increased and therefore potentially increases the number and amount of microneedles ultimately capable of penetrating the skin. This might be better appreciated by referring to FIG. 5 b.
  • The microneedles 32, 34 may comprise a mixture of a polymeric material and an active agent beneficial to skin. The array 22 may be formed by molding the microneedles 32, 34 using conventional molding techniques.
  • Another embodiment of the invention is shown in FIGS. 6a and 6b . In this case, a device 40, similar to device 20, is provided, which comprises array 41 comprising microneedles 42, 44, 46 of at least three or more different lengths.
  • It is known that different areas of the facial skin have different dermal thicknesses. For example, the tear troughs, that is, the skin directly under the eyes, have extremely thin dermal layers, while the chin region of the face has a relatively thick dermis. It is contemplated that by varying the multiple needle lengths, as described herein, various devices in accordance with the invention can be made which provide a desired penetration profile of selected facial areas.
  • In some embodiments of the invention, microneedles are provided which have a beneficial depth of penetration, depending upon the patient's age, skin type, and/or area of skin being treated. For example, in one aspect of the invention, a skin treatment device is provided which comprises a substrate having a first region including microneedles having a first length, and a second region adjacent the first region and including microneedles having a second length that is different from the first length.
  • Turning now to FIG. 7, in another embodiment, a patch device 50 is provided that includes certain regions with particular needle arrays, which takes into account variances in dermal thicknesses of a patient. This may facilitate efficient drug delivery to various areas of the face, for example. For example, device 50 is in the form of a patch having array 52 for the nose bridge, and a different array 54 for the thinner facial region adjacent the nose. The device 50 is thus in the form of a single patch that is capable of effectively delivering drugs or beneficial agents to different regions of the skin, in this case, the nose bridge and the cheeks and/or tear trough, at a depth of penetration suitable for the skin region, based on the different arrangements of microneedles.
  • Generally, in order for microneedles to effectively dissolve and release within the skin to provide a benefit for skin rejuvenation, the depth of penetration may be between about 25 μm to about 2000 μm, for example, about 100 μm to about 1000 μm. In some embodiments, the microneedles have a length of less than 100 μm, and in some embodiments, the microneedles have a length of greater than 1000 μm, for example, up to about 2000 μm. In some embodiments, the microneedles, for example, the longest microneedles in the arrangement, have a length of between about 200 μm and about 600 μm, for example, about 400 μm, or even more specifically, about 420 μm to about 480 μm.
  • In one embodiment, a skin treatment device in accordance with the invention comprises a substrate and spaced apart hyaluronic acid-based microneedles projecting from the substrate, wherein the microneedles have a length of between about 420 μm and 480 μm, a base of between about 200 μm and about 300 μm, for example, a base of about 270 μm, and a tip width of less than 20 μm, for example, a tip width of about 5 μm.
  • For use in the tear trough region, in one embodiment, the microneedles, for example, the first microneedles, have a length less than about 500 μm, for example, between about 100 μm to about 500 μm, for example, a length of about 400 μm, for example, a length of about 300 μm, for example, a length of about 200 μm. For use in the chin region, the microneedles have a length greater than about 500 μm, for example, a length of between about 500 μm to about 2000 μm, for example, a length of about 600 μm, for example, a length of about 700 μm, for example, a length of about 800 μm, for example, a length of up to about 1000 μm, of up to about 2000 μm.
  • In another embodiment, the first microneedles have a length of about 1000 μm and the second microneedles have a length of about 500 μm. For example, the first microneedles may be in the region of the patch for application on the nose of the patient, where the skin in relatively thick, and the second microneedles may be in a region of the patch that is intended for the regions of skin directly adjacent the nose, where the skin is relatively thin.
  • In other embodiments, the first microneedles have a length of about 800 μm and the second microneedles have a length of about 200 μm. In yet another embodiment, the first microneedles have a length of about 500 μm and the second microneedles have a length of about 300 μm.
  • It is further contemplated that the device may comprise microneedles having a third length different from the first and second length, and a fourth length different from the first second and third lengths.
  • Spacing between adjacent microneedles may be uniform or non-uniform across the microneedle arrangement. For example, in some embodiments, spacing between microneedles is substantially uniform. Spacing may be between about 100 μm and about 2000 μm, for example, 200 μm, about 300 μm, about 400 μm, about 500 μm, about 600 μm, about 700 μm, about 800 μm, about 900 μm, about 1000 μm, about 1100 μm, about 1200 μm, about 1300 μm, about 1400 μm, about 1500 μm, about 1600 μm, about 1700 μm, about 1800 μm, about 1900 μm, or about 2000 μm, or greater, between adjacent microneedles.
  • In yet another embodiment, illustrated in FIG. 8, the present invention provides a skin treatment device 70 comprising a plurality of stages, or layers 72, 74, 76, 78. The layers 72, 74, 76, 78 may be designed to be applied to the skin in an overlapping fashion. The device 70 provides custom treatment for a patient depending upon the type of skin, or the amount or type of active agent to be delivered. For example, device 70 may be used to create different layered microneedle patches 80, 82, each tailored to a patient's unique skin qualities.
  • Each of the layers, for example, layer 72, may comprise a substrate 72 having spacing or perforations 72 and microneedles 72 a located generally between the spacing. The needles 72 a may be throttled to permit a number of layers to be stacked on one another, with needles of adjacent layers extending in the spacing between needles of other adjacent layers.
  • For example, for use in a patient having a rougher, more deflective skin, layered patch 80 comprising fewer layers 72, 74, and thus a lower density of needles, may be utilized to treat the skin. For a patient having a relatively softer skin, a patch 82 comprising more layers, such as layers 72, 74, 76 and 78, and thus a higher density of needles, could be used to treat the skin. For example, a single layer, for example, layer 72 may be used for treatment of a patient having rough, more deflective skin. A layered patch 80, comprising a combination of layer 72 and layer 74, may be used for treatment of a patient having semi-rough, less deflective skin. A patient with relatively smooth skin may be treated with a denser needle array, for example, a layered patch 82 comprising a combination of layers 72, 74, 76 and 78.
  • The layers 72, 74, 76, 78 could be pre-assembled before being applied to the skin, or could be layered during a treatment session while on the skin.
  • In some embodiments, each of layers 72, 74, 76 and 78 comprises a different specific needle length, such that when the layers are placed together, the assembly provides a desired treatment profile.
  • For example, layer 72 may include only relatively long needles 72 a and layer 78 may comprise only relatively short needles 78 a. In some embodiments, each layer comprises needles of appropriate needle length to effectively deliver an equivalent amount of active agent per needle.
  • In some embodiments, each of layers 72, 74, 76 and 78 comprises a different, specific pharmaceutical, or other beneficial agent, such that when the layers are placed together, the assembly provides a desired treatment profile, for example, made up of a combination of such agents.
  • For example, layer 72 may include needles 72 a comprising hyaluronic acid and Vitamin C as an active agent, while layer 74 includes needles 74 a having hyaluronic acid and Vitamin E as an active agent. Thus, patch 80, comprising layered 72 and 74, can be used to deliver both hyaluronic acid, Vitamin C and Vitamin E.
  • In yet another embodiment, as show in simplified form in FIG. 9, a method of treating skin is provided. The method comprises drawing an area of skin 3 to be treated toward a microneedle device, for example, device 10, or any other microneedle device in accordance with the invention as described elsewhere herein. The method comprises using negative pressure, for example by means of a vacuum mechanism 90 having vacuum chamber 92, in order to stretch the skin and enhance penetration of microneedles into the skin 3. This method reduces deflection of the skin away from the needles and improves the number of needles that penetrate the skin and/or depth of needle penetration.
  • Any suitable vacuum or negative pressure mechanism may be used to accomplish more effective needle penetration in accordance with this embodiment. For example, in one embodiment, the vacuum mechanism 90 includes essentially no moving parts, and vacuum chamber 92 supplies negative pressure to draw the surface of skin 3 toward microneedle device 10. The microneedle device 10 can be flexibly sealed against the walls of the chamber such as by means of a rubber or other suitable material gasket, thus allowing the device 10 to move toward skin while maintaining a vacuum.
  • As depicted in FIG. 9, the skin 3 may experience maximum deflection in the central area within the vacuum chamber 92. It is contemplated that in order to compensate for uneven deflection, the microneedles at the perimeter of the device 10 can be made longer than the needles in the inner portion thereof. Another means to address uneven skin deflection caused by the vacuum is to provide an appropriately sized vacuum area so that the micro-needle penetration area is sufficient for therapeutic coverage but small enough to permit consistency. For example, as illustrated in FIG. 10, multiple vacuum chambers 94, for example, seven vacuum chambers, located within a single housing 96, may be used to provide more consistent needle penetration and to enable coverage of a larger skin area in single application.
  • Turning now to FIG. 11, in yet another embodiment of the invention, device 110 of the invention is in the form of a stretchable mask. Device 110 may be similar to devices 10, 20, 40, 50, 70, 80 and 82, and may include one or more of the features already described. Device 110 may have substrate in a generic face shape, for example, with cutouts 112 for the eyes, lips, and/or and any other areas. Either the substrate only, or the entire device 110 including the microneedles, can be made of a stretchable material. As illustrated, arrangements of microneedles of the device 110 can be different for treating different locations of the face. For example, the needle length, density of needles, or needle geometry can be altered depending on the region of the face they are intended to treat. For example, microneedles 112 are provided for treatment below the eye, microneedles 112 b are provided for treatment of the cheek region, and microneedles 112 c are provided for treatment of the chin region.
  • Alternatively, turning now to FIG. 12, instead of one large mask-like device such as shown in FIG. 11, in some embodiments, device 210 is provided which comprises separate, discrete patches 212 are provided for specific areas of the face. This is illustrated in FIG. 12. The ability of the discrete patches to overlap allows the patches to accommodate many potential face shapes and sizes. In this embodiment, area specific microneedle patches are applied independently across a patient's face. Each patch may include the same or different arrangements of microneedles, for example, arrangements 212 a, 212 b, 212 c. For example, the needle length, density of needles, type or dosage of beneficial agent, or even needle geometry can be altered depending on where on the region of the face they will be used to treat.
  • Another embodiment, illustrated in FIG. 13, is provided which generally comprises an assembly 310 comprising microneedle strips 312 which may be applied to skin in rows, or other patterns, to obtain the precise coverage desirable for a patient. Such strips 312 may be provided in the form of a roll 314 of tape 316. The tape 314 may have features that indicate which side of the tape contains the microneedles. This may be a color, text, or shape indication. This embodiment allows rapid large surface area application over a wide variety of patient anatomies.
  • Similar to unique needle geometries among the face specific patch embodiments, several strip “types” may be provided that can be used during a single procedure. Each strip may be used on specific areas of the face, with needles on each strip with unique needle length, density of needles, needle geometry, etc. The microneedle geometries may be unique to specific “tapes” to be applied on certain regions of the face.
  • Example Preparation of Microneedle Device in Accordance with an Embodiment, Using Hyaluronic Acid (HA)
  • Preparation of HA Gel Hydrate:
  • HA gel hydrates were made by hydrating low molecular weight (LMW) HA (Mw is about 340,000 to about 840,000 Da) in deionized (DI) water or phosphate buffered saline (PBS). For a 12 wt % of LMW HA, approximately 1.20 g of LMW HA and 8.80 g of DI water were mixed in a 20 mL syringe. The mixture was left at room temperature for 24 hours to achieve a uniform hydrogel. The gel was then transferred to a 1.0 mL syringes and centrifuged at 4000 rpm for 5.0 min.
  • HA Gel Casting:
  • The casting of HA gel includes two steps, casting and pre-concentrating. In the casting step, HA gel was cast on the negative silicone microneedle mold and upon evaporation of water at room temperature or in an oven, the solution formed a viscous paste on the top of the mold. For example, 0.65 mL of a 12 wt % HA gel was cast onto the center of the negative silicone mold. The gel together with the silicone mold was placed into an oven which was pre-set at 40° C. After 1.50 hours of incubation, the gel formed a paste and was removed from the oven for the compression step.
  • Pressing and Post-Incubation:
  • The HA paste together with the negative silicone microneedle mold was placed on a compressor. A PTFE film was placed on top of the HA paste. The compression pressure was set to 20 psi initially, then increased to 50 psi at a constant rate over a period of 30 seconds and held at this pressure for another 30 seconds.
  • Needle Formation:
  • After pressing, the PTFE film was removed and a flat layer of HA remained on top of the mold. The mold was then placed into a 40° C. oven for 2.5 hours. The dried micro-needle batch was then removed from the mold and sent for characterizations by SEM and x-ray CT.
  • Although the various embodiments of the invention have been described and illustrated with a certain degree of particularity, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the combination and various arrangement of parts, features and components can be resorted to by those skilled in the art without departing from the scope of the invention, as hereinafter claimed.

Claims (15)

What is claimed is:
1. A device effective to deliver a beneficial agent to the skin, the device comprising:
a substrate; and
an arrangement of microneedles projecting from the substrate;
the arrangement comprising first microneedles having a first length and second microneedles having a second length different from the first length;
the first and second microneedles comprising a mixture of a polymeric material and an active agent beneficial to skin.
2. The device of claim 1 wherein the polymeric material comprises hyaluronic acid.
3. The device of claim 2 wherein the polymeric material comprises crosslinked hyaluronic acid.
4. The device of claim 1 wherein the first length is at least about 20% greater in length than the second length.
5. The device of claim 1 wherein the first length is at least about 40% greater in length than the second length.
6. The device of claim 1 wherein the first length is at least about 60% greater in length than the second length.
7. The device of claim 1 wherein the first length is at least about 80% greater in length than the second length.
8. The device of claim 1 wherein the arrangement is in the form of an array in which the first and second microneedles are arranged in an alternating fashion.
9. A method of treating skin comprising applying the device of claim 1 to a region of skin to be treated in a manner capable of causing the first and second microneedles to penetrate the stratum corneum.
10. The method of claim 8 further comprising drawing the region of skin to be treated toward the device using suction or a vacuum.
11. A skin treatment assembly comprising:
a first patch having a first shape for covering a portion of a face to the treated and including a first array of microneedles;
a second patch having a second shape different from the first shape for covering another portion of a face to be treated and including a second array of microneedles different from the first array.
12. The assembly of claim 11 wherein the first array comprises microneedles having a first length and the second array comprises microneedles having a second length different from the first length.
13. The assembly of claim 11 wherein the first array comprises microneedles having a first spacing between adjacent microneedles and the second array comprises microneedles having a second spacing between adjacent microneedles the second spacing being different from the first spacing.
14. The assembly of claim 11 wherein the microneedles comprise a mixture of a polymeric material and an active agent beneficial to skin.
15. The device of claim 14 wherein the polymeric material comprises hyaluronic acid.
US14/671,690 2014-03-28 2015-03-27 Dissolvable microneedles for skin treatment Abandoned US20160279401A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US14/671,690 US20160279401A1 (en) 2015-03-27 2015-03-27 Dissolvable microneedles for skin treatment
US15/903,262 US10603477B2 (en) 2014-03-28 2018-02-23 Dissolvable microneedles for skin treatment
US16/834,731 US10987503B2 (en) 2014-03-28 2020-03-30 Dissolvable microneedles for skin treatment
US17/240,884 US20220080170A1 (en) 2014-03-28 2021-04-26 Dissolvable microneedles for skin treatment
US18/130,490 US20240033492A1 (en) 2014-03-28 2023-04-04 Dissolvable microneedles for skin treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/671,690 US20160279401A1 (en) 2015-03-27 2015-03-27 Dissolvable microneedles for skin treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/903,262 Continuation US10603477B2 (en) 2014-03-28 2018-02-23 Dissolvable microneedles for skin treatment

Publications (1)

Publication Number Publication Date
US20160279401A1 true US20160279401A1 (en) 2016-09-29

Family

ID=56974672

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/671,690 Abandoned US20160279401A1 (en) 2014-03-28 2015-03-27 Dissolvable microneedles for skin treatment
US15/903,262 Active 2035-04-05 US10603477B2 (en) 2014-03-28 2018-02-23 Dissolvable microneedles for skin treatment
US16/834,731 Active US10987503B2 (en) 2014-03-28 2020-03-30 Dissolvable microneedles for skin treatment

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/903,262 Active 2035-04-05 US10603477B2 (en) 2014-03-28 2018-02-23 Dissolvable microneedles for skin treatment
US16/834,731 Active US10987503B2 (en) 2014-03-28 2020-03-30 Dissolvable microneedles for skin treatment

Country Status (1)

Country Link
US (3) US20160279401A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018151832A1 (en) 2017-02-17 2018-08-23 Allergan, Inc. Microneedle array with active ingredient
CN108853713A (en) * 2018-07-17 2018-11-23 优微(珠海)生物科技有限公司 A kind of microneedle transdermal delivery biology facial mask
CN109718465A (en) * 2019-01-28 2019-05-07 深圳市中明科技股份有限公司 3D printing electret micropin promotees to absorb facial mask
WO2020037157A1 (en) 2018-08-15 2020-02-20 Allergan, Inc. Microneedle array with active ingredient
US20200147359A1 (en) * 2018-11-11 2020-05-14 Esthetic Education LLC Microneedle Array
CN111818953A (en) * 2018-01-07 2020-10-23 亚夫拉罕·阿米尔 High-load microneedles and compositions for skin improvement
US10952519B1 (en) 2020-07-16 2021-03-23 Elyse Enterprises LLC Virtual hub for three-step process for mimicking plastic surgery results
JP2021511124A (en) * 2018-01-18 2021-05-06 シンビア カンパニー リミテッド Implantable microneedles and their manufacturing methods
US11007358B2 (en) * 2016-09-01 2021-05-18 Hisamitsu Pharmaceutical Co., Inc. Microneedle sheet
WO2021113545A1 (en) 2019-12-03 2021-06-10 Transderm, Inc. Manufacture of microstructures
US11160497B1 (en) * 2020-07-16 2021-11-02 Elyse Enterprises LLC Software configuration for virtual skincare assessment and virtual cues
US11318293B2 (en) * 2018-11-26 2022-05-03 Massachusetts Institute Of Technology Single or multi-dose delivery platform for veterinary applications
WO2022098314A1 (en) * 2020-11-09 2022-05-12 National University Of Singapore A multi-layered sheet mask

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6850457B2 (en) * 2019-03-12 2021-03-31 シンクランド株式会社 How to collect the stratum corneum
US20210023019A1 (en) * 2019-07-26 2021-01-28 Pedram Hamrah Dermal patch for transdermal administration of ghrelin pathway blocker
CA3159272A1 (en) * 2019-11-22 2021-05-27 Veradermics Incorporated Microneedle patch for immunostimulatory drug delivery

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US20020138049A1 (en) * 1998-06-10 2002-09-26 Allen Mark G. Microneedle devices and methods of manufacture and use thereof
US20030069548A1 (en) * 2001-10-05 2003-04-10 Connelly Robert I. Microdevice and method of delivering of withdrawing a substance through the skin of an animal
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US6623457B1 (en) * 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US20150196359A1 (en) * 2014-01-10 2015-07-16 Sebacia, Inc. Methods for delivery of sub-surface array of absorber materials and methods of light irradiation therapy
US20150209563A1 (en) * 2012-09-13 2015-07-30 Avraham Amir Delivery devices and methods for skin augmentation

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5586466A (en) 1993-12-16 1996-12-24 Steiner; George A. Non-slip sleeve for float level sensor shaft
US6230051B1 (en) 1996-06-18 2001-05-08 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
DE60007290T2 (en) 1999-01-28 2004-09-23 Cyto Pulse Sciences, Inc. INTRODUCTION OF MACROMOLECULES IN CELLS
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
MXPA02005765A (en) 1999-12-10 2003-01-28 Alza Corp Skin treatment apparatus for sustained transdermal drug delivery.
US6565532B1 (en) 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
WO2002064193A2 (en) 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
US6946501B2 (en) 2001-01-31 2005-09-20 The Procter & Gamble Company Rapidly dissolvable polymer films and articles made therefrom
JP4090018B2 (en) 2002-02-18 2008-05-28 For Head株式会社 Functional micropile and manufacturing method thereof
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
WO2004108204A1 (en) 2003-06-10 2004-12-16 Medrx Co., Ltd. Process for producing pad base for transdermal drug administration, pad base for transdermal drug administration and needle
US8353861B2 (en) 2003-09-18 2013-01-15 Texmac, Inc. Applicator for applying functional substances into human skin
JP4210231B2 (en) 2004-03-25 2009-01-14 株式会社資生堂 Cosmetic method for improving skin wrinkles and wrinkle improving tool
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US20060100584A1 (en) 2004-08-10 2006-05-11 Orest Olejnik Needleless microprotrusion elastoplast system
JP5082053B2 (en) 2004-08-16 2012-11-28 イノチュア アイ・ピー リミテッド Manufacturing method of microneedle or microimplant
CA2518650A1 (en) 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
EP1845870A1 (en) 2004-11-18 2007-10-24 3M Innovative Properties Company Non-skin-contacting microneedle array applicator
CA2594291C (en) 2004-12-28 2012-03-06 Nabtesco Corporation Skin needle manufacturing apparatus and skin needle manufacturing method
US20060253079A1 (en) 2005-04-25 2006-11-09 Mcdonough Justin Stratum corneum piercing device
US8043250B2 (en) 2005-05-18 2011-10-25 Nanomed Devices, Inc. High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US20080269666A1 (en) 2005-05-25 2008-10-30 Georgia Tech Research Corporation Microneedles and Methods for Microinfusion
EP1888001B1 (en) 2005-06-10 2014-08-06 Syneron Medical Ltd. Patch for transdermal drug delivery
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US20070009587A1 (en) 2005-06-21 2007-01-11 Peter Daddona Method and device for coating a continuous strip of microprojection members
KR100728061B1 (en) 2005-08-10 2007-06-14 강승주 Transdermal patch having micro-scale needle array and method for manufacturing the same
JP5049268B2 (en) 2006-04-07 2012-10-17 久光製薬株式会社 Microneedle device and transdermal drug administration device with microneedle
KR100793615B1 (en) 2006-07-21 2008-01-10 연세대학교 산학협력단 A biodegradable solid type microneedle and methods for preparing it
US20090182306A1 (en) 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
US7785301B2 (en) 2006-11-28 2010-08-31 Vadim V Yuzhakov Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection
US8476243B2 (en) 2006-12-29 2013-07-02 Transderm, Inc. Methods and compositions for treating keratin hyperproliferative disorders
ES2817249T3 (en) 2007-04-16 2021-04-06 Corium Inc Microneedle matrices obtained by dissolution and casting containing an active principle
JP2008284318A (en) 2007-05-15 2008-11-27 Kosumedei Seiyaku Kk Microneedle for dosing, including living body origin matter
EP2153863B1 (en) 2007-05-15 2022-03-16 Hisamitsu Pharmaceutical Co., Inc. Method of coating microneedle
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
US8366677B2 (en) 2007-08-06 2013-02-05 Transderm, Inc. Microneedle arrays formed from polymer films
US20100221314A1 (en) 2007-10-18 2010-09-02 Hisamitsu Pharmaceutical Co., Inc. Microneedle Device
US8491534B2 (en) 2007-11-21 2013-07-23 Bioserentach Co., Ltd. Preparation for body surface application and preparation for body surface application-holding sheet
WO2009094394A1 (en) 2008-01-23 2009-07-30 Georgia Tech Research Corporation Microneedle devices and methods of drug delivery or fluid withdrawal
JP5267910B2 (en) 2008-02-28 2013-08-21 コスメディ製薬株式会社 Microneedle array
NZ588883A (en) 2008-03-31 2013-01-25 Altea Therapeutics Corp Permeant delivery system and methods for use thereof
JP2009254756A (en) 2008-04-14 2009-11-05 Kosumedei Seiyaku Kk Microneedle array
CN102105108B (en) 2008-05-21 2013-12-04 谢拉杰克特股份有限公司 Method of manufacturing solid solution peforator patches and uses thereof
JP5472673B2 (en) 2008-09-29 2014-04-16 コスメディ製薬株式会社 Microneedle array
CA2739876A1 (en) 2008-10-07 2010-04-15 Tuo Jin Phase-transition polymeric microneedles
WO2010056922A2 (en) 2008-11-12 2010-05-20 Kythera Biopharmaceuticals, Inc. Systems and methods for delivery of biologically active agents
CN102325563A (en) 2008-12-22 2012-01-18 昆士兰大学 Patch production
WO2010078323A1 (en) 2008-12-29 2010-07-08 Sung-Yun Kwon Method of manufacturing solid solution peforator patches and uses thereof
WO2010095456A1 (en) 2009-02-23 2010-08-26 株式会社メドレックス Applicator for microneedle array
JP2011012050A (en) * 2009-06-03 2011-01-20 Bioserentack Co Ltd Microneedle array using porous substrate and method for producing the same
CN102781463A (en) 2009-10-07 2012-11-14 戈诺珍公司 Methods and compositions for skin regeneration
US8834423B2 (en) 2009-10-23 2014-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
JP5495034B2 (en) 2010-02-22 2014-05-21 コスメディ製薬株式会社 Multi-needle microneedle patch
EA201290928A1 (en) 2010-03-19 2013-04-30 Оцука Фармасьютикал Ко., Лтд. CONTAINING PROTEOGLYCAN COMPOUND MICROIGLE
JP5868953B2 (en) 2010-04-28 2016-02-24 キンバリー クラーク ワールドワイド インコーポレイテッド Injection mold microneedle array and manufacturing method thereof
DE102010030864A1 (en) 2010-07-02 2012-01-05 Robert Bosch Gmbh Manufacturing method for a microneedle assembly and corresponding microneedle assembly and use
JP5808102B2 (en) 2010-07-22 2015-11-10 コスメディ製薬株式会社 Transdermal immunological preparation containing antigen and method for producing the same
JP5688752B2 (en) 2010-07-22 2015-03-25 コスメディ製薬株式会社 Transdermal absorption preparation and method for producing the same
JP5672554B2 (en) 2010-08-19 2015-02-18 Jcrファーマ株式会社 Composition for subcutaneous or transdermal absorption
ES2531577T3 (en) 2010-08-20 2015-03-17 Novartis Ag Needle sets for administration of soluble flu vaccine
US9089677B2 (en) 2011-01-25 2015-07-28 The Regents Of The University Of California Transcutaneous multimodal delivery system (TMDS)
US20120193840A1 (en) 2011-02-02 2012-08-02 Theraject, Inc. Method of manufacturing solid solution perforator patches
WO2012115207A1 (en) 2011-02-24 2012-08-30 久光製薬株式会社 Biologically active nonaqueous composition for microneedle devices, and biologically active nonaqueous composition adhering to microneedle
CA2829352A1 (en) 2011-03-07 2012-09-13 3M Innovative Properties Company Microneedle devices and methods
CA2829354C (en) 2011-03-07 2020-09-29 3M Innovative Properties Company Microneedle devices and methods
WO2012128363A1 (en) 2011-03-24 2012-09-27 コスメディ製薬株式会社 Pedf micro-needle array and method for producing same
TWI458504B (en) 2011-05-02 2014-11-01 Univ Nat Cheng Kung Patch for transdermal drug delivery and method of controlling drug release of the same by near-ir
GB201107642D0 (en) 2011-05-09 2011-06-22 Univ Cork Method
BR112013033803A2 (en) 2011-06-28 2017-02-14 Bioserentach Co Ltd formulation integrated with microneedle, and method for administering a substance
JP2013032324A (en) 2011-08-03 2013-02-14 Bioserentack Co Ltd Rapid-acting microneedle array patch preparation including local anesthetic
JP2013052202A (en) 2011-09-01 2013-03-21 Kosumedei Seiyaku Kk Dna vaccine microneedle
JP6121674B2 (en) 2011-09-12 2017-04-26 コスメディ製薬株式会社 Microneedle rapid dissolution method
DE102012017949A1 (en) 2011-09-28 2013-03-28 Sumitomo Wiring Systems, Ltd. Terminal fitting
US20130096532A1 (en) 2011-10-17 2013-04-18 Rutgers, The State University Of New Jersey Polymer-Based Micro-Needle Array Designs, Fabrication Processes, and Methods of Use Thereof for Drug Delivery
CN103889497A (en) 2011-10-20 2014-06-25 考司美德制药株式会社 Microneedle deposition technique
CN104105714B (en) 2011-12-21 2017-04-05 路博润高级材料公司 Prepare the method and thus obtained product of acrylate copolymer
JP5746101B2 (en) 2012-06-18 2015-07-08 コスメディ製薬株式会社 Rapid dissolution method of microneedles
WO2014026161A1 (en) 2012-08-10 2014-02-13 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
US20140276359A1 (en) 2013-03-15 2014-09-18 Plum Systems Co. Apparatus and method for tissue rejuvenation
ES2921174T3 (en) 2013-03-15 2022-08-19 Corium Inc Set of microstructures for the delivery of active agents, method of manufacturing the set of microstructures and liquid formulation thereof
US9987361B1 (en) 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020138049A1 (en) * 1998-06-10 2002-09-26 Allen Mark G. Microneedle devices and methods of manufacture and use thereof
US6623457B1 (en) * 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US20030069548A1 (en) * 2001-10-05 2003-04-10 Connelly Robert I. Microdevice and method of delivering of withdrawing a substance through the skin of an animal
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US20150209563A1 (en) * 2012-09-13 2015-07-30 Avraham Amir Delivery devices and methods for skin augmentation
US20150196359A1 (en) * 2014-01-10 2015-07-16 Sebacia, Inc. Methods for delivery of sub-surface array of absorber materials and methods of light irradiation therapy

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007358B2 (en) * 2016-09-01 2021-05-18 Hisamitsu Pharmaceutical Co., Inc. Microneedle sheet
WO2018151832A1 (en) 2017-02-17 2018-08-23 Allergan, Inc. Microneedle array with active ingredient
CN111818953A (en) * 2018-01-07 2020-10-23 亚夫拉罕·阿米尔 High-load microneedles and compositions for skin improvement
JP7055954B2 (en) 2018-01-18 2022-04-19 シンビア カンパニー リミテッド Implantable microneedles and their manufacturing methods
JP2021511124A (en) * 2018-01-18 2021-05-06 シンビア カンパニー リミテッド Implantable microneedles and their manufacturing methods
CN108853713A (en) * 2018-07-17 2018-11-23 优微(珠海)生物科技有限公司 A kind of microneedle transdermal delivery biology facial mask
CN108853713B (en) * 2018-07-17 2023-11-10 优微(珠海)生物科技有限公司 Microneedle transdermal drug delivery biological mask
WO2020037157A1 (en) 2018-08-15 2020-02-20 Allergan, Inc. Microneedle array with active ingredient
US20200147359A1 (en) * 2018-11-11 2020-05-14 Esthetic Education LLC Microneedle Array
US11318293B2 (en) * 2018-11-26 2022-05-03 Massachusetts Institute Of Technology Single or multi-dose delivery platform for veterinary applications
CN109718465A (en) * 2019-01-28 2019-05-07 深圳市中明科技股份有限公司 3D printing electret micropin promotees to absorb facial mask
WO2021113545A1 (en) 2019-12-03 2021-06-10 Transderm, Inc. Manufacture of microstructures
US11160497B1 (en) * 2020-07-16 2021-11-02 Elyse Enterprises LLC Software configuration for virtual skincare assessment and virtual cues
US10952519B1 (en) 2020-07-16 2021-03-23 Elyse Enterprises LLC Virtual hub for three-step process for mimicking plastic surgery results
WO2022098314A1 (en) * 2020-11-09 2022-05-12 National University Of Singapore A multi-layered sheet mask

Also Published As

Publication number Publication date
US10603477B2 (en) 2020-03-31
US20200316356A1 (en) 2020-10-08
US20180229017A1 (en) 2018-08-16
US10987503B2 (en) 2021-04-27

Similar Documents

Publication Publication Date Title
US10987503B2 (en) Dissolvable microneedles for skin treatment
EP3122332B1 (en) Dissolvable microneedles for skin treatment
US20150352345A1 (en) Microneedle, mould for producing same, and production method for same
US20150141910A1 (en) Microneedles for therapeutic agent delivery with improved mechanical properties
Sharma et al. Recent advances of chitosan composites in artificial skin: the next era for potential biomedical application
KR101678656B1 (en) Preparation method of functionality-enhanced hydrogel mask pack
JP2019034151A (en) Microneedle array for lips
CN106456955B (en) Micropin piece and percutaneous dosing adhesive preparation
US20240033492A1 (en) Dissolvable microneedles for skin treatment
CN111315438A (en) Transdermal drug delivery system
KR20170018541A (en) A functional implantable medical device
US20210361833A1 (en) Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation
JP2005306746A (en) Wrinkle therapeutic agent for face
KR102557479B1 (en) Film type patch and manufacturing method thereof
Zhuang et al. Targeting Diverse Wounds and Scars: Recent Innovative Bio‐design of Microneedle Patch for Comprehensive Management
CN108367101B (en) Method for producing biocompatible matrices with targeted structural design
KR20200062097A (en) Micro-spicule, Mold for Producing the Same and Method for Producing the Same
CN115151233A (en) Adhesive cosmetic containing natural moisturizing factor
CN116509789A (en) Composition for treating acne, microneedle array, preparation method thereof and drug delivery system

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHWAB, JUSTIN;AUGARTEN, MIKE;DOMINGUEZ, ZACHARY;AND OTHERS;SIGNING DATES FROM 20140516 TO 20140817;REEL/FRAME:036625/0864

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION